Comparison
Citicoline vs Sermorelin
Side-by-side of Citicoline and Sermorelin. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Citicoline
Citicoline supplement profile: CDP-choline as a phosphatidylcholine precursor, Cognizin dosing 250-2000 mg, cognition trials, stroke recovery evidence.
Sermorelin
Sermorelin peptide therapy uses a 29-amino-acid GHRH analog to raise endogenous GH. Dosing, half-life, sermorelin vs ipamorelin, and safety.
Effects at a glance
Citicoline
- •Choline donor and phosphatidylcholine precursor; oral bioavailability roughly 99%
- •Standard prescription medication for stroke recovery and vascular cognitive impairment in much of the world
- •Healthy-adult cognitive trials (Cognizin) report small gains in attention and working memory at 250 to 500 mg/day
- •ICTUS trial (n=2,298) was negative on stroke recovery in the modern thrombolysis era
- •Lower per-gram choline content than alpha-GPC (~18% vs ~40%), meaning smaller TMAO load at equivalent dose
- •Long uridine half-life (~56 hours) supports once or twice daily dosing
Sermorelin
- •Synthetic 29-amino-acid GHRH fragment; FDA approved 1997 for pediatric GH deficiency as Geref
- •Voluntarily discontinued by Serono in 2008 for commercial reasons; not safety-related
- •Compounded by 503A/503B pharmacies for off-label adult anti-aging and body-composition use
- •Produces physiologic pulsatile GH release; ~10 to 20 minute plasma half-life
- •Standard anti-aging clinic protocol: 200 to 500 mcg subcutaneously pre-bed, often with ipamorelin
- •Banned by WADA under S2 (peptide hormones, growth factors)
Side-by-side
| Attribute | Citicoline | Sermorelin |
|---|---|---|
| Category | supplement | peptide |
| Also known as | CDP-choline, cytidine 5'-diphosphocholine, Cognizin | Sermorelin acetate, GRF 1-29, Geref, GHRH (1-29) NH2 |
| Half-life (hr) ↗ | 56 | 0.25 |
| Typical dose (mg) ↗ | 500 | 0.3 |
| Dosing frequency | 1 to 2 times daily | 1-2x daily |
| Routes | oral, intravenous | subcutaneous |
| Onset (hr) | 1 | 0.25 |
| Peak (hr) | 2 | 0.5 |
| Molecular weight | 488.32 | 3357.88 |
| Molecular formula | C14H26N4O11P2 | C149H246N44O42S |
| Mechanism | Hydrolyzed to cytidine and choline after absorption; both cross the blood-brain barrier and are recombined intracellularly to reform CDP-choline, supporting phosphatidylcholine synthesis and acetylcholine production. | Synthetic 29-amino-acid GHRH fragment that binds the GHRH receptor on pituitary somatotrophs to stimulate endogenous pulsatile GH synthesis and release while preserving the GH-IGF-1 negative feedback loop. |
| Legal status | Dietary supplement (US, Cognizin GRAS); prescription medication in most of the world | FDA approved 1997 (Geref, pediatric GHD); voluntarily discontinued by Serono 2008; compounded by 503A/503B pharmacies for off-label adult use; banned by WADA |
| WADA status | allowed | banned |
| DEA / Rx | OTC supplement (US); Rx in most of the world | Rx only via compounding (no controlled-substance schedule) |
| Pregnancy | Insufficient data for routine use | Category C (historical labeling); not recommended in pregnancy |
| CAS | 987-78-0 | 86168-78-7 |
| PubChem CID | 13804 | 16129617 |
| Wikidata | Q411470 | Q416620 |
Safety profile
Citicoline
Common side effects
- mild GI upset
- headache
- restlessness
- occasional insomnia with evening dosing
Contraindications
- concurrent strong anticholinergic therapy
- established cardiovascular disease (TMAO concern, smaller than alpha-GPC)
Interactions
- anticholinergic medications: partial mutual antagonism(minor)
- cholinesterase inhibitors: additive cholinergic effect(minor)
- antimetabolite chemotherapy (5-FU): theoretical cytidine pathway interaction(minor)
Sermorelin
Common side effects
- injection-site pain or irritation
- transient flushing
- headache
- vivid dreams (pre-bed dosing)
Contraindications
- pregnancy
- active malignancy
- history of pituitary tumor
- diabetic retinopathy (theoretical)
- untreated hypothyroidism
Interactions
- ipamorelin: synergistic GH release via parallel GHRH and ghrelin pathways; standard anti-aging clinic pairing(minor)
- CJC-1295: pharmacologically redundant (both GHRH-pathway); typically not stacked(minor)
- insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
- corticosteroids: blunt GH response; reduce expected efficacy(moderate)
- levothyroxine (untreated hypothyroidism): untreated hypothyroidism blunts GH response; correct thyroid first(moderate)
Which Should You Take?
Citicoline comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. Sermorelin is the right call when one of the conditionals below applies.
- → If your priority is focus or working memory, pick Citicoline.
- → If your priority is stroke recovery, pick Citicoline.
- → If your priority is growth-hormone axis, pick Sermorelin.
- → If your priority is healthspan extension, pick Sermorelin.
Edge case: If you want to avoid FDA approved 1997 (Geref, pediatric GHD); voluntarily discontinued by Serono 2008; compounded by 503A/503B pharmacies for off-label adult use; banned by WADA, Citicoline is the more accessible choice.
Default choice: Citicoline. Lower friction to source, and broader goal coverage. Reach for Sermorelin only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Citicoline and Sermorelin?
Citicoline and Sermorelin differ in category (supplement vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Citicoline or Sermorelin?
Citicoline half-life is 56 hours; Sermorelin half-life is 0.25 hours.
Can you stack Citicoline with Sermorelin?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper